 | • レポートコード：MRC2203A793 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の抗血栓薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤分類別（血栓溶解薬、抗血小板薬、抗凝固薬）分析、投与経路別（経口、非経口）分析、用途別（肺塞栓症、深部静脈血栓症、心房細動、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の抗血栓薬市場規模：薬剤分類別（血栓溶解薬、抗血小板薬、抗凝固薬） ・世界の抗血栓薬市場規模：投与経路別（経口、非経口） ・世界の抗血栓薬市場規模：用途別（肺塞栓症、深部静脈血栓症、心房細動、その他） ・世界の抗血栓薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Sanofi S.A.、Bayer AG、Eli Lilly and Company、...） ・市場機会・将来の傾向 |
Thrombosis is a condition when the blood clot is formed called a thrombus. Thrombus prevents the blood flow in blood vessels and may cause the death of cells and serious medical conditions. Antithrombotic drugs are used to prevent or treat thrombus formation. The growing number of chronic diseases that lead to thrombosis coupled with the increase in geriatric population is expected to drive the market growth. In addition, many of the drugs of antithrombotics are off-patented and presence of generics with a lower cost are fuelling the market growth over the forecast period. Furthermore, the presence of strong drug pipelines such as Tecarfarin, TB-402 and others and their expected commercialization is projected to boost the market growth over the coming years. Moreover, unavailability of alternatives for antithrombotic drugs coupled with the new product developments and launches are expected to bolster the market growth. However, stringent regulatory policies and high cost of novel drugs are expected to hamper the market growth.
Key Market Trends
Parental Route of Administration Expected to Have Significant Share
- In the route of administration parenteral route is having significant share owing to its onset of action and presence of notable number of products in the market.
- In the application segment, deep vein thrombosis is expected to have a healthy growth rate over the forecast period owing to its prevalence and sedentary lifestyle among the population that is leading to cardiovascular diseases.
- According to the Center for Disease Control and Prevention (CDC), about 900,000 people each year affected by venous embolism. Furthermore, 10-30% of people will die within the month of diagnosis.
- The advancements in treatment therapies such as catheter-directed thrombolysis and others in the usage of antithrombotic drugs for better clinical outcomes are projected to boost the market growth over the forecast period. In addition ageing population around the world is expected to boost the market growth.
North America Projected to Grow at Significant Rate
North America region is expected to have significant market growth over the forecast period. The high prevalence of cardiac diseases and cancer are expected to fuel the regional market share. In addition, favourable reimbursement policies and well-established healthcare infrastructure coupled with growing healthcare expenditure expected to boost the market growth in North America.
According to the World Health Organization, an estimated 17.9 million people died due to cardiovascular diseases in the year 2016. Out of these most of the deaths occured in Low-and Middle-income Countries. The Asia Pacific projected to have significant market growth owing to a large number of patient pool suffering from cardiac diseases and the presence of a strong generic drug market in emerging countries. In addition, manufactures interest in expanding to these Asian emerging countries expected to boost the market growth in the near future.
Competitive Landscape
Antithrombotic drugs market is highly competitive having a majority number of local or regional players. Market players are focusing on drug development, product launches and geographic expansions. Key market players operating in the market include Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Ko. KG and Aspen Holdings among the others
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Cardiac and Hereditary Diseases
4.2.2 Growing Demand For Novel Oral Anticoagulants Coupled with the Ageing Population
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.3.2 High Cost and Side effects of Anti thrombotic Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Thrombolytic Drugs
5.1.2 Anti-platelet Drugs
5.1.3 Anticoagulants
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.3 By Application
5.3.1 Pulmonary Embolism
5.3.2 Deep Vein Thrombosis
5.3.3 Atrial Fibrillation
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Sanofi S.A.
6.1.2 Bayer AG
6.1.3 Eli Lilly and Company
6.1.4 AstraZeneca plc
6.1.5 Boehringer Ingelheim International GmbH
6.1.6 Otsuka Pharmaceutical Co., Ltd.
6.1.7 Novartis AG
6.1.8 Aspen Holdings
6.1.9 Bristol-Myers Squibb Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS